about
Activin A impairs insulin action in cardiomyocytes via up-regulation of miR-143A high-coverage shRNA screen identifies TMEM129 as an E3 ligase involved in ER-associated protein degradationExploring Reovirus Plasticity for Improving Its Use as Oncolytic VirusModification of mammalian reoviruses for use as oncolytic agentsHuman adenovirus type 35 vector for gene therapy of brain cancer: improved transduction and bypass of pre-existing anti-vector immunity in cancer patients.The 45-kDa form of Pdx-1 does not result from post-translational modifications.Ube2j2 ubiquitinates hydroxylated amino acids on ER-associated degradation substrates.Exploitation of herpesvirus immune evasion strategies to modify the immunogenicity of human mesenchymal stem cell transplants.Locally-delivered T-cell-derived cellular vehicles efficiently track and deliver adenovirus delta24-RGD to infiltrating glioma.Cell replacement therapies: is it time to reprogram?Isolation of reovirus T3D mutants capable of infecting human tumor cells independent of junction adhesion molecule-A.Adenoviral vectors stimulate glucagon transcription in human mesenchymal stem cells expressing pancreatic transcription factors.β-Cell Generation: Can Rodent Studies Be Translated to Humans?Proteasomal Degradation of Proinsulin Requires Derlin-2, HRD1 and p97.Immune responses against adenoviral vectors and their transgene products: a review of strategies for evasion.The Epstein-Barr Virus Glycoprotein gp150 Forms an Immune-Evasive Glycan Shield at the Surface of Infected CellsThe adenovirus capsid: major progress in minor proteins.Cross-species transfer of viruses: implications for the use of viral vectors in biomedical research, gene therapy and as live-virus vaccines.Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashionGene therapy in The Netherlands: highlights from the Low Countries.Reappraisal of biosafety risks posed by PERVs in xenotransplantation.How not to be seen: immune-evasion strategies in gene therapy.Genetically engineered human islets protected from CD8-mediated autoimmune destruction in vivo.Replacement of native adenovirus receptor-binding sites with a new attachment moiety diminishes hepatic tropism and enhances bioavailability in mice.Adenovirus-derived vectors for prostate cancer gene therapy.Clinical adenoviral gene therapy for prostate cancer.Emergence of viral diseases: mathematical modeling as a tool for infection control, policy and decision making.Non-human viruses developed as therapeutic agent for use in humans.Animal models in virus research: their utility and limitations.Biosafety of non-human therapeutic viruses in clinical gene therapy.Changing faces in virology: the dutch shift from oncogenic to oncolytic viruses.Off-label prescription of genetically modified organism medicines in europe: emerging conflicts of interest?Serpina1 (alpha1-AT) is synthesized in the osteoblastic stem cell niche.Replicating reoviruses with a transgene replacing the codons for the head domain of the viral spike.Mammalian orthoreovirus T3D infects U-118 MG cell spheroids independent of junction adhesion molecule-A.New role of signal peptide peptidase to liberate C-terminal peptides for MHC class I presentation.Heterogeneous reovirus susceptibility in human glioblastoma stem-like cell cultures.Herpesvirus microRNAs for use in gene therapy immune-evasion strategies.A cathepsin-cleavage site between the adenovirus capsid protein IX and a tumor-targeting ligand improves targeted transduction.Truncating the i-leader open reading frame enhances release of human adenovirus type 5 in glioma cells.
P50
Q24297012-62BDD208-4DA8-4F5D-8B8A-83742D472A02Q24297209-694583BD-6968-440E-9FE3-D08E9FEAAF86Q26771799-19CD1327-A47D-4892-B6D8-E50C0862DA96Q26771799-F715E7A0-4D3F-451A-9793-657E25C3B23FQ28264900-04A60BCB-63BF-41D1-871D-678199EC4825Q28264900-08434080-7ACB-41ED-834E-2D5135D48132Q33262597-86B89137-31DB-44E7-9DC2-8D4DC2E8C30BQ33325254-0EDDD932-BE28-49BF-A395-1DD1A1B27967Q33590955-0FB7AFA6-0230-4DBE-9444-B8A7D2AEFED5Q33590955-63E75D68-EDD9-48C0-AF1A-3E3FB3A9059BQ33799067-FFD12886-4832-4A2A-A8D7-BD718D4EA36BQ34102273-575B11C5-CFDC-4248-A4B9-BBAB6FBA5450Q34102273-687824ED-8C95-4B8F-8F5E-56BCA2786558Q34267315-2117855E-4698-4B3F-A19E-335BA144028CQ34460916-2B877CFB-F8C1-4962-A1C0-8BEAE9164E94Q34460933-A5758F36-9C79-4F51-B34E-DFAF595A78FEQ35294804-6FFE7FE8-50DA-4AF5-897C-747BEF822401Q35672979-0DC64D48-58DD-47AB-A026-2D19CBF8AE89Q35749783-299D8C1A-F05A-4AAE-89A5-028DF7530492Q35989470-2D012245-01AE-48EB-B30C-FC3283F5E494Q36138215-8A4E393C-E890-4B18-AEEB-3A4B355EB6ECQ36178513-28652980-DE37-41E0-96D0-E17F469A626DQ36829259-6D7987AC-1834-421A-BCA1-2C0957CD591BQ36920198-925805A0-1181-4EF4-BDDE-45E06BF954FAQ36920198-D0E10F43-7517-4191-8ACA-4189776AD73BQ36995344-5A7A4D0E-7262-44CC-8F11-F9CAE2FB14ECQ37018636-84D33A45-71D2-489A-9C08-CA15FC3297E1Q37073103-2F1C0CFD-1388-44AF-9564-60C1144EBD99Q37330624-29E07578-A596-4B32-9CA3-5EA4787CB399Q37330624-EA53AAA9-4B3A-4FB9-AD0D-73A6ADDC5434Q37641338-8813AE26-C6AC-499E-B8C8-E3880316D07EQ37650343-5AAD8F36-F46A-49C5-96D2-68274D451582Q37706540-344D7125-4D96-4A08-A233-1462129B7653Q37706540-C66382E7-B15A-4A41-A0AF-E5BE81EB38C7Q37874215-CD40AE6F-5CB0-4474-97D7-728CA919AB94Q38043556-ED7D11C6-1B6C-415F-9C1F-AE7AE55B6059Q38176421-E77FAA2E-8991-4529-B97E-3A521464F8E8Q38241666-688E9A5D-8A6F-40AC-B4C5-6291FDF95597Q38241666-96BD7198-6D05-4B46-B0AC-14ADC764B4BDQ38255478-872D7077-00E0-4DAB-A9D6-281C89593261
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Rob C Hoeben
@ast
Rob C Hoeben
@en
Rob C Hoeben
@es
Rob C Hoeben
@nl
Rob C Hoeben
@sl
type
label
Rob C Hoeben
@ast
Rob C Hoeben
@en
Rob C Hoeben
@es
Rob C Hoeben
@nl
Rob C Hoeben
@sl
prefLabel
Rob C Hoeben
@ast
Rob C Hoeben
@en
Rob C Hoeben
@es
Rob C Hoeben
@nl
Rob C Hoeben
@sl
P1053
A-5771-2008
P106
P21
P31
P3829
P496
0000-0001-9443-8377